Emergent BioSolutions initiates Phase Ib chronic lymphocytic leukemia study Equities.com Nov 02, 2012 (Datamonitor via COMTEX) -- Emergent BioSolutions Inc., a biopharmaceutical company, has announced the initiation of a Phase Ib study, or Protocol 16009, of TRU-016 in combination with rituximab for patients with previously untreated ... |
